002868.SZ
绿康生化
SZSE · Healthcare · C 制造业 · CN
CNY 21.57
−2.35%Year over year
Reported trailing growth
- Revenue
- -20.3%
- EBITDA
- —
- EBIT
- +78.0%
- EPS
- +76.5%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +16.1%
- EBITDA
- +90.7%
- EBIT
- +70.0%
- Net income
- +68.7%
- EPS
- +68.5%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026